Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 Baseline characteristics of participants by exclusion and by type of treatment

From: Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer—a retrospective cohort study

Variable

By exclusion

By type of treatment

Excluded

Included

p

Group 1

Group 2

p

n

300

68

-

45

23

-

Age (years)

57.1 ± 13.3

54.3 ± 13.4

0.116

55.2 ± 13.1

52.7 ± 14.1

0.475

BMI (kg/m2)

27 ± 5.6

25.7 ± 4.8

0.069

25.7 ± 4.8

25.7 ± 5

0.983

Hypertension

118/300 (39.3%)

24/68 (35.3%)

0.583

17/45 (37.8%)

7/23 (30.4%)

0.602

Diabetes mellitus

41/300 (13.7%)

6/68 (8.8%)

0.322

3/45 (6.7%)

3/23 (13%)

0.399

Hyperlipidaemia

36/300 (12%)

8/68 (11.8%)

1

3/45 (6.7%)

5/23 (21.7%)

0.109

Current smoking

44/300 (14.7%)

13/68 (19.1%)

0.357

8/45 (17.8%)

5/23 (21.7%)

0.75

MACE

14/300 (4.7%)

2/68 (2.9%)

0.746

0/45 (0%)

2/23 (4.3%)

0.111

Previous chemotherapy

-

-

-

12/45 (26.7%)

0/23 (0%)

0.006

EF (%)

-

-

-

64.3 ± 4.2

65 ± 4.7

0.527

DT (msec)

-

-

-

212.5 ± 1.3

229.1 ± 1.2

0.225

E/e’

-

-

-

6.5 ± 1.3

6.4 ± 1.3

0.834

  1. Data are mean ± SD or n/total (%). p values based on independent samples t-tests or chi-square tests. p < 0.05 was considered as statistically significant. Group 1 included patients who received taxane-based chemotherapy treatment without anthracycline. Group 2 included patients who received anthracycline followed by taxane-based treatment. BMI, body mass index; MACE, major adverse cardiac events (prior acute myocardial infarction (ICD-10: I21x, I22x) or unstable angina (ICD-10: I200), ischaemic or haemorrhagic stroke (ICD-10: I60x-I64x); peripheral arterial disease (ICD-10: I738, I739)); EF, ejection fraction; DT, deceleration time; E/ e’, ratio of early diastolic flow peak velocity of the mitral valve (E) and early diastolic peak velocity of mitral valve annulus (e’). Hypertension, hyperlipidaemia and diabetes mellitus were diagnosed based on medication use (at least one drug for their treatment) and the diagnosis was coded in the medical record at least three times by a proper ICD-10 code (hypertension: I10xx, hyperlipidaemia: E78xx; diabetes mellitus: E10xx, E11xx or E14xx)). Previous chemotherapy was defined as anthracycline or anti-HER2 treatment beyond 365 days. Of the 12 patients, 10 received anthracycline chemotherapy and 6 received Anti-HER2 therapy
Back to article page

Cardio-Oncology

ISSN: 2057-3804

Contact us